Hanger D P, Hughes K, Woodgett J R, Brion J P, Anderton B H
Department of Neuroscience, Institute of Psychiatry, London, UK.
Neurosci Lett. 1992 Nov 23;147(1):58-62. doi: 10.1016/0304-3940(92)90774-2.
Glycogen synthase kinase-3 (GSK-3) reduced the mobility of human tau on SDS-PAGE, prevented binding of the monoclonal antibody (mAb), Tau.1, and induced binding of the mAb 8D8. Recombinant tau phosphorylated by GSK-3 aligned on SDS-PAGE with the abnormally phosphorylated tau (PHF-tau) associated with the paired helical filaments in Alzheimer's disease brain. Phosphorylated serine396 (numbering of the largest human brain tau isoform) was identified as a binding site on tau for mAb 8D8. The localisation of GSK-3 within granular structures in pyramidal cells indicates that GSK-3 alpha and GSK-3 beta may have a role in the production of PHF-tau in Alzheimer's disease.
糖原合酶激酶-3(GSK-3)降低了人tau蛋白在SDS-PAGE上的迁移率,阻止了单克隆抗体(mAb)Tau.1的结合,并诱导了mAb 8D8的结合。经GSK-3磷酸化的重组tau蛋白在SDS-PAGE上的迁移与阿尔茨海默病脑中与双螺旋丝相关的异常磷酸化tau蛋白(PHF-tau)一致。磷酸化的丝氨酸396(最大的人脑tau异构体的编号)被确定为mAb 8D8在tau蛋白上的结合位点。GSK-3在锥体细胞颗粒结构内的定位表明,GSK-3α和GSK-3β可能在阿尔茨海默病中PHF-tau的产生中起作用。